Targeting these factors through combinatorial strategies, such as blockade of IL‐10 or CXCR4, may enhance CAR T‐cell efficacy and overcome therapeutic resistance in CLL patients. The gene discussed is IL10; the disease is B-cell chronic lymphocytic leukemia.